Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors - Competitive Landscape, Market and Pipeline Analysis 2018

Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors - Competitive Landscape, Market and Pipeline Analysis 2018

  • Pages: 127
  • Geography: Global
  • Delivery Timeline: 24 Hours
  • Publication: Dec, 2017
  • SKU: DISR0014
  • Single User License
    (20% Off)
    $1,750.00
  • Site License
    (30% Off)
    $3,500.00
  • Global License
    (40% Off)
    $5,250.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight's, "Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors - Competitive Landscape,
Market and Pipeline Analysis 2017",
report provides comprehensive insights about pipeline drugs across Cyclin Dependent Kinase 4/6 inhibitors. A key objective of the report is to establish the understanding for the therapeutic competitive landscape for this mechanism of action.
It provides the marketed product details in this area.
It also covers the pipeline drugs that fall under Cyclin Dependent Kinase 4/6 inhibitors including their comparative analysis at various stages covering Filed, Phase II, Phase I, Pre-clinical, and inactive products, therapeutics assessment by monotherapy and combination products and molecule type.
The report also provides the market drivers and barriers for CDK 4/6 inhibitors.
The report is built using data and information sourced from proprietary databases,
primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines,
News websites, Government Websites, Trade Journals,
White papers, Magazines, Trade associations, Books, Industry Portals,
Industry Associations and access to available databases.

Executive Summary
Overview
Marketed Drugs
Pipeline Therapeutics
Last Stage Products (Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I)
Pre-clinical Stage Products
Therapeutic Assessment:
Active Products
Inactive Products
Market Drivers and Barriers
Appendix

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330
Outside India: +1(919)321-6187

Email

info@delveinsight.com

Address

New Delhi-110075, India

Latest Tweets

Copyright © 2018 Delveinsight.